SBIR-STTR Award

Novel Treatment for Drug-Induced Respiratory Depression. N01da-14-2239.
Award last edited on: 11/28/16

Sponsored Program
SBIR
Awarding Agency
NIH : NIDA
Total Award Amount
$148,583
Award Phase
1
Solicitation Topic Code
NIDA
Principal Investigator
Arnold Lippa

Company Information

RespireRx Pharmaceuticals (AKA: Cortex Pharmaceuticals Inc)

126 Valley Road Suite C
Glen Rock, NJ 07452
   (949) 727-3157
   info@cortexpharm.com
   www.cortexpharm.com
Location: Multiple
Congr. District: 05
County: Bergen

Phase I

Contract Number: N43DA140065
Start Date: 00/00/00    Completed: 00/00/00
Phase I year
2014
Phase I Amount
$148,583
Using plethysmographic measurements in various groups of rats, the proposed studies will determine the potency, latency to onset and duration of action of CX1942 when adminisstered either prior to, simultaneously with or subsequent to administration of either an opiate (morphine or fentanyl), a benzodiazepine (diazeman or alprazolam) in combination with an opiate or a benzodiazepine in combination with ethanol. PUBLIC HEALTH RELEVANCE

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
----
Phase II Amount
----